Stock Research for ADXS

ADXS
Current Price

$1.8150


Latest Update: 2018-02-22 16:00:00

High
$ 1.8200
Low
$ 1.8000
Close
$ 1.8000
Volume
239638
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ADXS Stock Chart & Research Data

The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ADXS Due diligence Resources & Stock Charts

The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADXS Detailed Price Forecast - CNN Money CNN View ADXS Detailed Summary - Google Finance
Yahoo View ADXS Detailed Summary - Yahoo! Finance Zacks View ADXS Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ADXS Trends & Analysis - Trade-Ideas Barrons View ADXS Major Holders - Barrons
NASDAQ View ADXS Call Transcripts - NASDAQ Seeking View ADXS Breaking News & Analysis - Seeking Alpha
Spotlight View ADXS Annual Report - CompanySpotlight.com OTC Report View ADXS OTC Short Report - OTCShortReport.com
TradeKing View ADXS Fundamentals - TradeKing Charts View ADXS SEC Filings - Bar Chart
WSJ View Historical Prices for ADXS - The WSJ Morningstar View Performance/Total Return for ADXS - Morningstar
MarketWatch View the Analyst Estimates for ADXS - MarketWatch CNBC View the Earnings History for ADXS - CNBC
StockMarketWatch View the ADXS Earnings - StockMarketWatch MacroAxis View ADXS Buy or Sell Recommendations - MacroAxis
Bullish View the ADXS Bullish Patterns - American Bulls Short Pains View ADXS Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ADXS Stock Mentions - StockTwits PennyStocks View ADXS Stock Mentions - PennyStockTweets
Twitter View ADXS Stock Mentions - Twitter Invest Hub View ADXS Investment Forum News - Investor Hub
Yahoo View ADXS Stock Mentions - Yahoo! Message Board Seeking Alpha View ADXS Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ADXS - SECform4.com Insider Cow View Insider Transactions for ADXS - Insider Cow
CNBC View ADXS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADXS - OTC Markets
Yahoo View Insider Transactions for ADXS - Yahoo! Finance NASDAQ View Institutional Holdings for ADXS - NASDAQ


Stock Charts

FinViz View ADXS Stock Insight & Charts - FinViz.com StockCharts View ADXS Investment Charts - StockCharts.com
BarChart View ADXS Stock Overview & Charts - BarChart Trading View View ADXS User Generated Charts - Trading View


Latest Financial News for ADXS

Advaxis looks to raise $20 million via share offering
Posted on Thursday February 22, 2018

Developing new cancer therapies, alone, is a daunting mission. Couple that with a volatile stock market , and companies like Advaxis Inc. are at a big disadvantage. To secure enough capital to push innovative products through the pipeline, a stock offering may be needed.


Advaxis Prices $20.0 Million Public Offering of Common Stock
Posted on Thursday February 22, 2018

Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $2.00 per share.


Advaxis Announces Proposed Public Offering of Common Stock
Posted on Wednesday February 21, 2018

Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.


Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
Posted on Tuesday February 13, 2018

Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization Application to the European Medicines Agency for the company’s lead Lm Technology product candidate, axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, ...


Advaxis Prices $20.0 Million Public Offering of Common Stock
Business Wire (press release) - 12 hours ago
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of its ...
Advaxis Inc. (ADXS) Plunges 28.29% on February 22 - Equities.com
Advaxis to raise US$20mln as it looks to advance portfolio of cancer treatments - Proactive Investors UK

Advaxis Inc. (ADXS) Settles Into New 52-Week Low on February 22 Session
Equities.com - 4 hours ago
Shares of Advaxis Inc. (ADXS) sank into a new 52-week low yesterday, and could be a company to watch at the open. The company's stock fell to as low as $1.80 yesterday after opening at $1.97.

Advaxis Takes Its First Step Towards Regulatory Approval
Seeking Alpha - Feb 14, 2018
Advaxis filed its Marketing Authorization Application to the EMA for European marketing approval for its metastatic cervical cancer treatment axalimogene filolisbac.

Advaxis Announces Proposed Public Offering of Common Stock
Business Wire (press release) - Feb 21, 2018
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends to ...

Enter a stock symbol to view the stock details.